Here are the 10-K annual reports from Insight Molecular Diagnostics Inc. (IMDX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow IMDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMDX filings page.
Insight Molecular Diagnostics Inc. is a diagnostics technology company focused on molecular tests for transplanted organ rejection, supported by an intellectual property portfolio in transplant and oncology. Its flagship GraftAssure family measures donor-derived cell-free DNA, offered as a CLIA-lab test and kitted products developed with Bio-Rad.
In 2025 the company began a clinical trial for its GraftAssureDx in vitro diagnostic kit and submitted a data package to the FDA on March 25, 2026, initially targeting kidney transplants. CMS provides coverage for GraftAssureCore and increased reimbursement to $2,753 per result.
The 10-K highlights continued operating losses, with a net loss of $50.2 million in 2025 and an accumulated deficit of $400.8 million, and notes reliance on external financing until test revenues can cover expenses. Key risks include limited near-term revenue concentration in a few tests, intense competition, reimbursement uncertainty, extensive regulatory requirements in the U.S. and abroad, and the need to protect and enforce patents and trade secrets. The company had 58 employees as of December 31, 2025.